Oppenheimer Asset Management Inc. Bei Gene, Ltd. Transaction History

Oppenheimer Asset Management Inc.

$7.62 Billion
Q2 2024

A detailed history of Oppenheimer Asset Management Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 26,924 shares of BGNE stock, worth $6.29 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

26,924

Previous 18,124 48.55%

Holding current value

$6.29 Million

Previous $2.83 Million 35.53%

% of portfolio

0.05%

Previous 0.04%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$129.52 - $174.32 $1.14 Million - $1.53 Million	8,800 Added 48.55%	26,924 $3.84 Million
Q1 2024 May 06, 2024	BUY	$141.8 - $181.47 $213,692 - $273,475	1,507 Added 9.07%	18,124 $2.83 Million
Q4 2023 Feb 13, 2024	BUY	$158.67 - $201.58 $446,814 - $567,649	2,816 Added 20.4%	16,617 $3 Million
Q3 2023 Nov 07, 2023	BUY	$179.87 - $225.13 $357,221 - $447,108	1,986 Added 16.81%	13,801 $2.48 Million
Q2 2023 Aug 02, 2023	BUY	$178.3 - $266.78 $76,669 - $114,715	430 Added 3.78%	11,815 $2.11 Million
Q1 2023 May 10, 2023	BUY	$215.53 - $274.5 $20,906 - $26,626	97 Added 0.86%	11,385 $2.45 Million
Q4 2022 Feb 06, 2023	SELL	$125.51 - $229.3 $81,958 - $149,732	-653 Reduced 5.47%	11,288 $2.48 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $34,531 - $52,986	-262 Reduced 2.15%	11,941 $1.61 Million
Q2 2022 Aug 08, 2022	BUY	$121.11 - $216.05 $31,004 - $55,308	256 Added 2.14%	12,203 $1.98 Million
Q1 2022 May 12, 2022	SELL	$146.52 - $269.56 $189,157 - $348,001	-1,291 Reduced 9.75%	11,947 $2.25 Million
Q4 2021 Feb 02, 2022	BUY	$248.56 - $389.34 $64,377 - $100,839	259 Added 2.0%	13,238 $3.59 Million
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $1,747 - $2,821	7 Added 0.05%	12,979 $4.71 Million
Q2 2021 Aug 03, 2021	BUY	$292.75 - $367.01 $157,792 - $197,818	539 Added 4.34%	12,972 $4.45 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $246,826 - $361,867	-947 Reduced 7.08%	12,433 $4.33 Million
Q4 2020 Feb 11, 2021	BUY	$221.31 - $316.61 $94,499 - $135,192	427 Added 3.3%	13,380 $3.46 Million
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $95,346 - $144,365	504 Added 4.05%	12,953 $3.71 Million
Q2 2020 Aug 11, 2020	BUY	$123.9 - $195.41 $15,115 - $23,840	122 Added 0.99%	12,449 $2.35 Million
Q1 2020 May 08, 2020	BUY	$121.84 - $173.19 $1.3 Million - $1.85 Million	10,660 Added 639.47%	12,327 $1.52 Million
Q4 2019 Feb 07, 2020	SELL	$115.78 - $208.34 $30,218 - $54,376	-261 Reduced 13.54%	1,667 $276,000
Q3 2019 Oct 31, 2019	SELL	$120.61 - $148.29 $5,909 - $7,266	-49 Reduced 2.48%	1,928 $236,000
Q2 2019 Aug 09, 2019	SELL	$113.99 - $146.86 $35,222 - $45,379	-309 Reduced 13.52%	1,977 $245,000
Q1 2019 Apr 24, 2019	SELL	$122.82 - $151.83 $68,656 - $84,872	-559 Reduced 19.65%	2,286 $302,000
Q4 2018 Jan 30, 2019	SELL	$107.01 - $175.15 $321 - $525	-3 Reduced 0.11%	2,845 $399,000
Q3 2018 Oct 26, 2018	BUY	$152.62 - $189.66 $434,661 - $540,151	2,848 New	2,848 $490,000

Others Institutions Holding BGNE

# of Institutions

212

Shares Held

45.1M

Call Options Held

106K

Put Options Held

93.1K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $24.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account

Oppenheimer Asset Management Inc. Bei Gene, Ltd. Transaction History